Jarnes J, Pillai N, Ahmed A, Shrestha S, Stark M, Whitley C
Mol Genet Metab Rep. 2025; 42():101179.
PMID: 39802096
PMC: 11720876.
DOI: 10.1016/j.ymgmr.2024.101179.
Liang Q, Catalano F, Vlaar E, Pijnenburg J, Stok M, van Helsdingen Y
Mol Ther Methods Clin Dev. 2022; 27:109-130.
PMID: 36284764
PMC: 9573825.
DOI: 10.1016/j.omtm.2022.09.010.
Monda E, Rubino M, Lioncino M, Di Fraia F, Pacileo R, Verrillo F
Front Pediatr. 2021; 9:632293.
PMID: 33718303
PMC: 7947260.
DOI: 10.3389/fped.2021.632293.
van der Meijden J, Kruijshaar M, Harlaar L, Rizopoulos D, van der Beek N, van der Ploeg A
J Inherit Metab Dis. 2018; 41(6):1205-1214.
PMID: 29556838
PMC: 6326992.
DOI: 10.1007/s10545-018-0166-3.
Schneider J, Burmeister L, Rudser K, Whitley C, Jarnes Utz J
Mol Genet Metab Rep. 2016; 8:24-7.
PMID: 27408821
PMC: 4932620.
DOI: 10.1016/j.ymgmr.2016.06.002.
Childhood Pompe disease: clinical spectrum and genotype in 31 patients.
van Capelle C, van der Meijden J, van den Hout J, Jaeken J, Baethmann M, Voit T
Orphanet J Rare Dis. 2016; 11(1):65.
PMID: 27189384
PMC: 4870771.
DOI: 10.1186/s13023-016-0442-y.
Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study.
Anderson L, Henley W, Wyatt K, Nikolaou V, Waldek S, Hughes D
J Inherit Metab Dis. 2014; 37(6):945-52.
PMID: 24906254
DOI: 10.1007/s10545-014-9728-1.
Extended phenotype description and new molecular findings in late onset glycogen storage disease type II: a northern Italy population study and review of the literature.
Remiche G, Ronchi D, Magri F, Lamperti C, Bordoni A, Moggio M
J Neurol. 2013; 261(1):83-97.
PMID: 24158270
DOI: 10.1007/s00415-013-7137-2.
Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months.
Schneider I, Hanisch F, Muller T, Schmidt B, Zierz S
Wien Med Wochenschr. 2012; 163(1-2):40-4.
PMID: 23160972
DOI: 10.1007/s10354-012-0153-5.
Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study.
van der Beek N, de Vries J, Hagemans M, Hop W, Kroos M, Wokke J
Orphanet J Rare Dis. 2012; 7:88.
PMID: 23147228
PMC: 3551719.
DOI: 10.1186/1750-1172-7-88.
Two cases of Pompe's disease: case report and review of literature.
Jegadeeswari A, Amuthan V, Janarthanan R, Murugan S, Balasubramanian S
Indian Heart J. 2012; 64(2):214-6.
PMID: 22572506
PMC: 3861064.
DOI: 10.1016/S0019-4832(12)60067-4.
Qualitative and quantitative skeletal muscle ultrasound in late-onset acid maltase deficiency.
Zaidman C, Malkus E, Siener C, Florence J, Pestronk A, Al-Lozi M
Muscle Nerve. 2011; 44(3):418-23.
PMID: 21755514
PMC: 3193541.
DOI: 10.1002/mus.22088.
Cardiovascular abnormalities in late-onset Pompe disease and response to enzyme replacement therapy.
Forsha D, Li J, Smith P, van der Ploeg A, Kishnani P, Pasquali S
Genet Med. 2011; 13(7):625-31.
PMID: 21543987
PMC: 3138812.
DOI: 10.1097/GIM.0b013e3182142966.
CRIM-negative infantile Pompe disease: 42-month treatment outcome.
Rohrbach M, Klein A, Kohli-Wiesner A, Veraguth D, Scheer I, Balmer C
J Inherit Metab Dis. 2010; 33(6):751-7.
PMID: 20882352
DOI: 10.1007/s10545-010-9209-0.
Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
Sun B, Zhang H, Bird A, Li S, Young S, Koeberl D
J Gene Med. 2009; 11(10):913-20.
PMID: 19621331
PMC: 3622249.
DOI: 10.1002/jgm.1372.
Temporal neuropathologic and behavioral phenotype of 6neo/6neo Pompe disease mice.
Sidman R, Taksir T, Fidler J, Zhao M, Dodge J, Passini M
J Neuropathol Exp Neurol. 2008; 67(8):803-18.
PMID: 18648322
PMC: 2743262.
DOI: 10.1097/NEN.0b013e3181815994.
Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
McVie-Wylie A, Lee K, Qiu H, Jin X, Do H, Gotschall R
Mol Genet Metab. 2008; 94(4):448-455.
PMID: 18538603
PMC: 2774491.
DOI: 10.1016/j.ymgme.2008.04.009.
Ultrastructural analysis of development of myocardium in calreticulin-deficient mice.
Lozyk M, Papp S, Zhang X, Nakamura K, Michalak M, Opas M
BMC Dev Biol. 2006; 6:54.
PMID: 17112388
PMC: 1660575.
DOI: 10.1186/1471-213X-6-54.
Pompe disease diagnosis and management guideline.
Kishnani P, Steiner R, Bali D, Berger K, Byrne B, Case L
Genet Med. 2006; 8(5):267-88.
PMID: 16702877
PMC: 3110959.
DOI: 10.1097/01.gim.0000218152.87434.f3.
The natural course of non-classic Pompe's disease; a review of 225 published cases.
Winkel L, Hagemans M, van Doorn P, Loonen M, Hop W, Reuser A
J Neurol. 2005; 252(8):875-84.
PMID: 16133732
DOI: 10.1007/s00415-005-0922-9.
